Shanghai, China

Bojun Li

This inventor holds 1 USPTO granted patent. Top assignees: Shanghai Pharmaceuticals Holdings Co., Ltd., Zhejiang University. Active years: 2016.


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bojun Li: Innovator in Quinazoline Derivatives

Introduction

Bojun Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on quinazoline derivatives. His research focuses on developing compounds with enhanced anti-tumor activity, which has important implications for cancer treatment.

Latest Patents

Bojun Li holds a patent for a quinazoline derivative, which includes a preparation method, intermediate, composition, and application. The patent describes a quinazoline derivative represented by Formula (I) and its pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs. This invention is notable for its improved anti-tumor activity, providing a promising avenue for cancer therapies.

Career Highlights

Throughout his career, Bojun Li has worked with notable organizations, including Shanghai Pharmaceuticals Holdings Co., Ltd. and Zhejiang University. His experience in these institutions has allowed him to advance his research and contribute to the development of new pharmaceutical solutions.

Collaborations

Bojun Li has collaborated with esteemed colleagues such as Guangxin Xia and Jingkang Shen. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Bojun Li's innovative research on quinazoline derivatives exemplifies the potential of pharmaceutical advancements in cancer treatment. His contributions continue to inspire future developments in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…